Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Advanced Breast Cancer

Hecht, Keith A; Selby, Christopher

doi:10.1177/1060028018793656

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of eIF3a in fetal tissues is higher than that in postnatal tissues, and eIF3a is expressed in intestinal, stomach, lung, liver, kidney and heart tissues during the embryonic period, and some of them will continue until postnatal. [9][10] The cacO-2 cell line after eIF3a knockout can inhibit its differentiation. It is speculated that eIF3a is expressed in embryonic tissues and growth tissues and may play a role in promoting cell differentiation.…”

Section: Discussionmentioning

confidence: 99%

Expression of eIF3A and eIF4E in ovarian cancer and its relationship with prognosis

Guo¹

2022

SPR

View full text Add to dashboard Cite

To investigate the role of eIF3A and eIF4E in ovarian cancer and their relationship with prognosis. The differential expression of eIF3A and eIF4 genes in ovarian cancer tissues and cells was analyzed by Gene Expression Omnibus (GEO). The target genes of eIF3A and eIF4 were searched by Cytoscape in STRING database. The relationship between eIF3A and eIF4E and prognosis was analyzed by TCGA database. The expression of eIF3A and eIF4E in ovarian cancer was verified by immunohistochemistry. The expressions of eIF3A and eIF4E were detected in ovarian cancer tissues, and compared with normal tissues, the expressions of eIF3A and eIF4E were higher in OC tissues, and the difference was statistically significant compared with the para-cancer group (P<0.05). Immunohistochemical results of clinical samples further verified this conclusion. TCGA database analysis showed that the expression of eIF3A and eIF4E was related to the median survival time of patients, and ENO was found to be the downstream target gene of eIF4.The expressions of eIF3a and eIF4E are closely related to the occurrence, development and poor prognosis of ovarian cancer, and they are expected to become unique molecular markers for clinical diagnosis, treatment and prognosis of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of eIF3A and eIF4E in ovarian cancer and its relationship with prognosis

Guo¹

2022

SPR

View full text Add to dashboard Cite

show abstract

“…Palbociclib, Abemaciclib and Ribociclib all generated significant improvements in median progression free survival (PFS) when combined with an endocrine drug for the hormone receptor-positive advanced breast cancer patients9, 10.…”

Section: Introductionmentioning

confidence: 99%

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

Xiu¹,

Xu²,

Li³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Endocrine resistance in hormone receptor positive breast cancer patients urges us to develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to reverse its resistance. Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by Federal Drug Administration and the European Medicines Agency for the treatment of advanced and metastatic HR+/HER2-breast cancer. However, no consistent conclusion has been reached to its application in other types of breast cancer. Therefore, the purpose of our study was to overview the clinical trials about the beneficial effects of Palbociclib, Ribociclib and Abemaciclib in breast cancer with their tolerable adverse effects, and discuss their resistant mechanisms thus looking for useful biomarkers to predict the efficiency of the CDK4/6 inhibitors. The CDK4/6 inhibitors application after the support of preclinic and clinic data will be helpful to provide other alternatively suitable strategies for different types of breast cancer patients.

show abstract

“…The use of a CDK inhibitor prevents hyperphosphorylation of the pRb, resulting in cell arrest in the G1-phase, which has an indirect antitumor effect in cancer cells with an intact Rb-mediated checkpoint. 8 …”

Section: Introductionmentioning

confidence: 99%

“…The first-generation CDK4/6 inhibitors had low specificity, resulting in inadequate clinical efficacy and intolerable toxicities; however, second-generation agents are now available and have demonstrated a higher efficacy compared to hormone therapy alone for advanced HR+/HER2− breast cancer and also a more manageable toxicity profile. 8 These agents include palbociclib, ribociclib, and abemaciclib. 8 The United States Food and Drug Administration (FDA) has approved CDK inhibitors for commercial use in the United States, although there is no study comparing them head to head.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Fernandes

Adashek

Barreto

et al. 2018

DIC

View full text Add to dashboard Cite

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2− advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.

show abstract

Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Advanced Breast Cancer

Abstract: The CDK inhibitors should be used in combination with endocrine therapies for the treatment of ABC. Efficacy of the 3 agents is similar. Selection within the class should include consideration of adverse effects and drug interactions.

Cited by 8 publications

References 42 publications

Expression of eIF3A and eIF4E in ovarian cancer and its relationship with prognosis

Expression of eIF3A and eIF4E in ovarian cancer and its relationship with prognosis

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Contact Info

Product

Resources

About